Pfizer, Valneva to stop Lyme disease vaccine trial in some patients
"The discontinuation of these participants was not due to any safety concerns with the investigational vaccine and was not prompted by a participant-reported adverse event," the companies said.
Advertisement
Paris: U.S. drugmaker Pfizer Inc and French vaccine company Valneva will stop testing an experimental Lyme disease vaccine in roughly half of the patients recruited in a U.S. trial, the companies said on Friday.
The late-stage trial was expected to include around 6,000 participants aged 5 and older in areas where Lyme disease, usually caused by poppyseed-sized ticks, is highly endemic. Studies were stopped at some sites due to violations of clinical trial guidelines by a third-party organization conducting the trial, the companies said, without disclosing the locations.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.